Avenue Biosciences
United States
- Palo Alto, California
- 13/01/2026
- Seed
- $7,500,000
Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers.
Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biology and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland.
Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities.
- Industry Biotechnology Research
- Website https://www.avenuebiosciences.com/
- LinkedIn https://www.linkedin.com/company/avenue-biosciences/
SetSale | $2,000,000 | (Mar 19, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
Beautiful.ai | $45,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)
Homaio | $4,135,744 | (Mar 19, 2026)
Foresight(UK) | $25,000,000 | (Mar 19, 2026)
VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)